Summit Therapeutics Inc. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Summit Therapeutics Inc. (SMMT) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $1.61 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2020-11-16
- Summit Therapeutics Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2020-09-30 was $1.61M, a 61.99% decline year-over-year.
- Summit Therapeutics Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2020-06-30 was $1.16M, a 73.37% decline year-over-year.
- Summit Therapeutics Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2019-09-30 was $4.23M.
- Summit Therapeutics Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2019-06-30 was $4.36M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 11 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | $1.61M 10-Q · filed 2020-11-16 | $2.77M derived: sum of 2 quarters · filed 2020-11-16 | $7.71M 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $1.16M 8-K · filed 2020-09-29 | $6.11M 8-K · filed 2020-09-29 | |||
| 2019-12-31 | $16.57M 8-K · filed 2020-09-29 | ||||
| 2019-09-30 | $4.23M 10-Q · filed 2020-11-16 | $8.58M derived: sum of 2 quarters · filed 2020-11-16 | $14.25M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $4.36M 8-K · filed 2020-09-29 | $10.02M 8-K · filed 2020-09-29 | |||
| 2019-01-31 | $17.38M 8-K · filed 2020-09-29 | ||||
| 2018-01-31 | $2.31M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |